Viatris Inc. (BIT:1VTRS)
Italy · Delayed Price · Currency is EUR | Market Cap | 19.42B +84.3% |
| Revenue (ttm) | 12.97B +4.3% |
| Net Income | -535.23M |
| EPS | -0.47 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 7.06 |
| Dividend | 0.41 (2.68%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 414 |
| Open | 15.56 |
| Previous Close | 15.67 |
| Day's Range | 15.50 - 15.56 |
| 52-Week Range | 8.49 - 15.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Viatris
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Viatris price target raised to $28 from $26 at UBS
UBS raised the firm’s price target on Viatris (VTRS) to $28 from $26 and keeps a Buy rating on the shares.
Viatris price target raised to $21 from $20 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Viatris (VTRS) to $21 from $20 and keeps a Neutral rating on the shares.
Viatris Earnings Call Transcript: Q3 2026
Q3 results supported higher 2026 guidance, led by North America and Greater China, despite supply constraints in Europe and emerging markets. Pacira is expected to add 2027 accretion and long-term growth potential.
Viatris Slides: Q3 2026
Viatris has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Viatris Earnings release: Q3 2026
Viatris released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Viatris Quarterly report: Q3 2026
Viatris has published its Q3 2026 quarterly earnings report on November 5, 2026.
Viatris reports Q3 adjusted EPS 71c, consensus 64c
Reports Q3 revenue $3.75B, consensus $3.79B. “Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business,” said Scott A. Smith, CEO, Viatr...
Viatris raises FY26 adjusted EPS view to $2.56-$2.63 from $2.45-$2.59
Consensus $2.51. Narrows FY26 revenue view to $14.7B-$14.9B from $14.55B-$14.95B, consensus $14.78B. Raises FY26 adjusted EBITDA view to $4.45B-$4.55B from $4.3B-$4.5B. “We are very pleased with the o...
Viatris Reports Third-Quarter 2026 Financial Results
Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Jap...
Viatris Announces Quarterly Dividend
PITTSBURGH, Nov. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that on November 2, 2026, its Board of Directors declared a quarterly dividend of $0....
Viatris commences tender offer to acquire Pacira for $36.50 per share in cash
Viatris (VTRS) announced that Peach Purchaser Sub, a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock…
Viatris commences tender offer to acquire Pacira for $36.50 per share in cash
08:43 EDT Viatris (VTRS) commences tender offer to acquire Pacira (PCRX) for $36.50 per share in cash
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary o...
Viatris price target raised to $14 from $13 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Viatris (VTRS) to $14 from $13 and keeps a Neutral rating on the shares. The firm is reviewing the…
Viatris price target raised to $20 from $18 at JPMorgan
JPMorgan raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Neutral rating on the shares as part of a Q3 earnings preview. Published first…
Viatris announces FDA approval of ryzumvi for treatment of presbyopia in adults
Viatris (VTRS) announced that the U.S. FDA has approved ryzumvi for the treatment of presbyopia in adults. Ryzumvi is currently approved in the United States for the treatment of pharmacologically-ind...
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, ...
Pacira upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Pacira (PCRX) to Neutral from Underweight with a $36.50 price target after Viatris (VTRS) agreed to acquire the company for $36.50 per share in cash. The firm has…
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
Viatris: Pacira deal expected to be immediately accretive to financial guidance
“The proposed transaction is expected to be immediately accretive to our financial guidance metrics,” said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris (VTRS). ...
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
07:45 EDT Viatris (VTRS) to acquire Pacira (PCRX) for $36.50 per share in cash, or $1.65B
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
Viatris (VTRS) and Pacira BioSciences (PCRX) announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock…
Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion
Viatris said on Thursday it will buy Pacira Biosciences for $1.65 billion, adding the pain therapy maker's products to its portfolio.
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructur...